undamentalytics Newsletter
Sign in

Krystal Biotech, Inc. revenue

Krystal Biotech, Inc.'s revenue was $389m in fiscal 2025, up 33.9% on the year before. Over the last twelve months it was $470m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue0051291389470
Growth on the year before———+473.0%+33.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Krystal Biotech, Inc. $470m 26.0% 280.1%
Arcutis Biotherapeutics, Inc. $464m 76.1% 241.4%
Cormedix Inc. $462m 280.5% 1135.4%
Ardelyx, Inc. $451m 16.8% 75.9%
Adma Biologics, Inc. $512m 8.0% 35.0%
Novavax Inc $414m -61.6% -36.3%

Compare with peers

Head to head: ARQT vs KRYSCRMD vs KRYSARDX vs KRYSADMA vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Krystal Biotech, Inc.